Clinical Significance of Serum Soluble CD Molecules to Assess Disease Activity in Vitiligo | Dermatology | JAMA Dermatology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Silverberg  JI, Silverberg  NB.  Association between vitiligo extent and distribution and quality-of-life impairment.  JAMA Dermatol. 2013;149(2):159-164.PubMedGoogle ScholarCrossref
Shi  Y-L, Weiland  M, Li  J,  et al.  MicroRNA expression profiling identifies potential serum biomarkers for non-segmental vitiligo.  Pigment Cell Melanoma Res. 2013;26(3):418-421.PubMedGoogle ScholarCrossref
Speeckaert  R, van Geel  N, Vermaelen  KV,  et al.  Immune reactions in benign and malignant melanocytic lesions: lessons for immunotherapy.  Pigment Cell Melanoma Res. 2011;24(2):334-344.PubMedGoogle ScholarCrossref
Russell  SE, Moore  AC, Fallon  PG, Walsh  PT.  Soluble IL-2Rα (sCD25) exacerbates autoimmunity and enhances the development of Th17 responses in mice.  PLoS One. 2012;7(10):e47748.PubMedGoogle ScholarCrossref
Yeo  UC, Yang  YS, Park  KB,  et al.  Serum concentration of the soluble interleukin-2 receptor in vitiligo patients.  J Dermatol Sci. 1999;19(3):182-188.PubMedGoogle ScholarCrossref
Caixia  T, Hongwen  F, Xiran  L.  Levels of soluble interleukin-2 receptor in the sera and skin tissue fluids of patients with vitiligo.  J Dermatol Sci. 1999;21(1):59-62.PubMedGoogle ScholarCrossref
Honda  Y, Okubo  Y, Koga  M.  Relationship between levels of soluble interleukin-2 receptors and the types and activity of vitiligo.  J Dermatol. 1997;24(9):561-563.PubMedGoogle ScholarCrossref
Huang  J, Jochems  C, Anderson  AM,  et al.  Soluble CD27-pool in humans may contribute to T cell activation and tumor immunity.  J Immunol. 2013;190(12):6250-6258.PubMedGoogle ScholarCrossref
Goules  A, Tzioufas  AG, Manousakis  MN, Kirou  KA, Crow  MK, Routsias  JG.  Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseases.  J Autoimmun. 2006;26(3):165-171.PubMedGoogle ScholarCrossref
Myśliwiec  H, Flisiak  I, Baran  A, Górska  M, Chodynicka  B.  Evaluation of CD40, its ligand CD40L and Bcl-2 in psoriatic patients.  Folia Histochem Cytobiol. 2012;50(1):75-79.PubMedGoogle ScholarCrossref
Dang  LV, Nilsson  A, Ingelman-Sundberg  H,  et al.  Soluble CD27 induces IgG production through activation of antigen-primed B cells.  J Intern Med. 2012;271(3):282-293.PubMedGoogle ScholarCrossref
Zhou  L, Shi  YL, Li  K,  et al.  Increased circulating Th17 cells and elevated serum levels of TGF-beta and IL-21 are correlated with human non-segmental vitiligo development.  Pigment Cell Melanoma Res. 2015;28(3):324-329.PubMedGoogle ScholarCrossref
Elela  MA, Hegazy  RA, Fawzy  MM, Rashed  LA, Rasheed  H.  Interleukin 17, interleukin 22 and FoxP3 expression in tissue and serum of non-segmental vitiligo: a case- controlled study on eighty-four patients.  Eur J Dermatol. 2013;23(3):350-355.PubMedGoogle Scholar
Rashighi  M, Harris  JE.  Interfering with the IFN-γ/CXCL10 pathway to develop new targeted treatments for vitiligo.  Ann Transl Med. 2015;3(21):343.PubMedGoogle Scholar
Yang  L, Wei  Y, Sun  Y,  et al.  Interferon-gamma inhibits melanogenesis and induces apoptosis in melanocytes: a pivotal role of CD8+ cytotoxic T lymphocytes in vitiligo.  Acta Derm Venereol. 2015;95(6):664-670.PubMedGoogle ScholarCrossref
Wang  X, Wang  Q, Wu  J,  et al.  Increased expression of CXCR3 and its ligands in vitiligo patients and CXCL10 as a potential clinical marker for vitiligo.  Br J Dermatol. 2016;174(6):1318-1326.PubMedGoogle ScholarCrossref
Harris  JE, Harris  TH, Weninger  W, Wherry  EJ, Hunter  CA, Turka  LA.  A mouse model of vitiligo with focused epidermal depigmentation requires IFN-γ for autoreactive CD8+ T-cell accumulation in the skin.  J Invest Dermatol. 2012;132(7):1869-1876.PubMedGoogle ScholarCrossref
Peperzak  V, Veraar  EA, Xiao  Y,  et al.  CD8+ T cells produce the chemokine CXCL10 in response to CD27/CD70 costimulation to promote generation of the CD8+ effector T cell pool.  J Immunol. 2013;191(6):3025-3036.PubMedGoogle ScholarCrossref
Harris  JE, Rashighi  M, Nguyen  N,  et al.  Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA).  J Am Acad Dermatol. 2016;74(2):370-371.PubMedGoogle ScholarCrossref
Craiglow  BG, King  BA.  Tofacitinib citrate for the treatment of vitiligo: a pathogenesis-directed therapy.  JAMA Dermatol. 2015;151(10):1110-1112.PubMedGoogle ScholarCrossref
Harris  JE.  IFN-γ in vitiligo: is it the fuel or the fire?  Acta Derm Venereol. 2015;95(6):643-644.PubMedGoogle Scholar
Original Investigation
November 2016

Clinical Significance of Serum Soluble CD Molecules to Assess Disease Activity in Vitiligo

Author Affiliations
  • 1Department of Dermatology, Ghent University Hospital, Ghent, Belgium
JAMA Dermatol. 2016;152(11):1194-1200. doi:10.1001/jamadermatol.2016.2366
Key Points

Question  Are serum soluble CD (sCD) levels associated with disease activity in vitiligo?

Findings  In this cross-sectional study of 93 patients with vitiligo, serum sCD25 and sCD27 were significantly linked with disease activity in vitiligo. Moreover, sCD27 was associated with a capacity to indicate probable future disease progression.

Meaning  This study supports the role of sCD25 and sCD27 as biomarkers to assess vitiligo activity and indicate likely future progression.


Importance  It is difficult to determine disease activity in vitiligo owing to the absence of inflammatory signs, such as erythema or scaling. A biomarker that could confirm active disease and indicate likely future disease progression would therefore be of considerable value.

Objective  To investigate whether soluble CD27 (sCD27), sCD25, or sCD40L could be valuable biomarkers to determine disease activity in vitiligo and indicate likely future progression.

Design, Setting, and Participants  A combined cross-sectional and prospective study was conducted at the department of dermatology at Ghent University Hospital between February 24, 2012, and December 12, 2015. Ninety-three patients with vitiligo were enrolled, including 83 individuals with nonsegmental vitiligo and 10 with segmental vitiligo. Blood sampling was performed, and sCD25, sCD27, and sCD40L were measured in serum.

Main Outcomes and Measures  The associations between sCD levels, disease activity, and future progression were investigated.

Results  Of the 93 patients included in the study, 51 were women (55%); median (interquartile range) age was 36.5 (26.0-49.8) years. Both sCD27 (21.5 ng/mL [16.1-30.0 ng/mL] vs 18.4 ng/mL [12.5-22.1 ng/mL]; P = .006) and sCD25 (2.6 ng/mL [2.1-3.4 ng/mL] vs 2.2 ng/mL [1.7-2.4 ng/mL]; P = .002) levels were associated with active disease. Moreover, a statistically significant link with disease progression after 3 to 6 months was found for sCD27 (21.7 [17.0-29.1] vs 16.6 [13.5-23.7]; P = .02) but not for sCD25 (2.8 ng/mL [2.2-3.4 ng/mL] vs 2.3 [1.9-2.8 ng/mL]; P = .053). Further in vitro experiments showed a correlation between sCD25 and interferon γ (r = 0.562, P = .005), interleukin 10 (r = 0.453, P = .03), and sCD27 secretion (r = 0.549, P = .007). No associations were found for sCD40L levels.

Conclusions and Relevance  This study demonstrates increased levels of sCD27 and sCD25 in patients with active vitiligo. Moreover, these results provide the first evidence that these markers have a capacity to indicate the probability of future disease progression, which supports their role as biomarkers in vitiligo.